Young G Shin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5810757/publications.pdf

Version: 2024-02-01

52 papers	849 citations	623188 14 h-index	500791 28 g-index
52 all docs	52 docs citations	52 times ranked	1287 citing authors

#	Article	IF	Citations
1	Lead identification of novel and selective TYK2 inhibitors. European Journal of Medicinal Chemistry, 2013, 67, 175-187.	2.6	80
2	Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 4521-4536.	2.9	72
3	Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor. Drug Metabolism and Disposition, 2011, 39, 1840-1849.	1.7	69
4	Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models. Journal of Medicinal Chemistry, 2015, 58, 401-418.	2.9	69
5	Increasing the Throughput and Productivity of Caco-2 Cell Permeability Assays Using Liquid Chromatography-Mass Spectrometry: Application to Resveratrol Absorption and Metabolism. Combinatorial Chemistry and High Throughput Screening, 2003, 6, 757-767.	0.6	51
6	A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry. Drug Metabolism and Disposition, 2011, 39, 1460-1467.	1.7	49
7	Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. British Journal of Clinical Pharmacology, 2012, 74, 788-796.	1.1	48
8	Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). Journal of Medicinal Chemistry, 2015, 58, 8182-8199.	2.9	47
9	Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development. Pharmaceutical Research, 2015, 32, 3508-3525.	1.7	44
10	Comparison of Metabolic Soft Spot Predictions of CYP3A4, CYP2C9 and CYP2D6 Substrates Using MetaSite and StarDrop. Combinatorial Chemistry and High Throughput Screening, 2011, 14, 811-823.	0.6	34
11	New Bioactive Coumarins fromKielmeyeraalbopunctata. Journal of Natural Products, 2003, 66, 634-637.	1.5	28
12	Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. Biochemical Pharmacology, 2018, 151, 59-68.	2.0	24
13	Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin. Korean Journal of Physiology and Pharmacology, 2017, 21, 107.	0.6	19
14	Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing. Drug Metabolism and Disposition, 2013, 41, 1319-1328.	1.7	17
15	Screening Drugs for Metabolic Stability Using Pulsed Ultrafiltration Mass Spectrometry. Combinatorial Chemistry and High Throughput Screening, 2002, 5, 59-64.	0.6	14
16	Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Design, Development and Therapy, 2017, Volume11, 1043-1053.	2.0	13
17	Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibodyâ€“Drug Conjugate. Molecules, 2020, 25, 1515.	1.7	13
18	Opportunities in low-level radiocarbon microtracing: applications and new technology. Future Science OA, 2016, 2, FSO74.	0.9	12

#	Article	IF	Citations
19	Determination of loperamide in Mdr1a/1b knock-out mouse brain tissue using matrix-assisted laser desorption/ionization mass spectrometry and comparison with quantitative electrospray-triple quadrupole mass spectrometry analysis. Archives of Pharmacal Research, 2011, 34, 1983-1988.	2.7	11
20	Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Molecules, 2019, 24, 2754.	1.7	11
21	High Performance Liquid Chromatographic Determination of Ginsenosides Using Photoreduction Fluorescence Detection. Journal of Liquid Chromatography and Related Technologies, 1995, 18, 2077-2088.	0.9	10
22	Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling. Molecules, 2019, 24, 1295.	1.7	9
23	Qualification and application of a liquid chromatographyâ€“quadrupole timeâ€ofâ€flight mass spectrometric method for the determination of trastuzumab in rat plasma. Biomedical Chromatography, 2016, 30, 625-631.	0.8	8
24	Preparation and evaluation of oral dissolving film containing local anesthetic agent, lidocaine. Journal of Pharmaceutical Investigation, 2017, 47, 575-581.	2.7	7
25	A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse. Pharmaceutics, 2018, 10, 69.	2.0	7
26	A single liquid chromatographyâ€“quadrupole timeâ€ofâ€flight mass spectrometric method for the quantification of total antibody, antibodyâ€conjugated drug and free payload of antibodyâ€“drug conjugates. Biomedical Chromatography, 2018, 32, e4229.	0.8	6
27	Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Pharmaceutics, 2018, 10, 260.	2.0	6
28	In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385. Molecules, 2020, 25, 1106.	1.7	6
29	Validation of a method for the determination of thiocyanate in human plasma by UV/VIS spectrophotometry and application to a Phase I clinical trial of GDC-0425. Translational and Clinical Pharmacology, 2015, 23, 59.	0.3	5
30	Quantification and application of a liquid chromatographyâ€“tandem mass spectrometric method for the determination of WKYMVm peptide in rat using solidâ€phase extraction. Biomedical Chromatography, 2018, 32, e4107.	0.8	5
31	Liquid chromatographyâ€high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics. Biomedical Chromatography, 2020, 34, e4855.	0.8	5
32	Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay. Pharmaceutics, 2021, 13, 125.	2.0	5
33	Qualification and application of a liquid chromatographyâ€“tandem mass spectrometric method for the determination of human AÎ²1-40 and AÎ²1-42 peptides in transgenic mouse plasma using micro-elution solid phase extraction. Archives of Pharmacal Research, 2014, 37, 636-644.	2.7	4
34	Validation of a liquid chromatographyâ€triple quadrupole mass spectrometric method for the determination of 5â€nitroâ€5â€²â€hydroxyâ€indirubinâ€3â€²â€oxime (AGMâ€130) in human plasma and its application to a microdose clinical trial. Biomedical Chromatography, 2016, 30, 323-329.	0.8	4
35	Qualification and Application of a Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method for the Determination of Adalimumab in Rat Plasma. Pharmaceutics, 2018, 10, 61.	2.0	4
36	Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats. Pharmaceutics, 2019, 11, 354.	2.0	4

#	Article	IF	Citations
37	Profiling and Identification of Omeprazole Metabolites in Mouse Brain and Plasma by Isotope Ratio-Monitoring Liquid Chromatography-Mass Spectrometric Method. Life, 2020, 10, 115.	1.1	4
38	Validation and application of a liquid chromatographyâ€“tandem mass spectrometric method for the determination of GDC-0879 and its metabolite in dog plasma using solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 354-361.	1.4	3
39	Validation and application of a liquid chromatographyâ€tandem mass spectrometric method for the determination of GDCâ€0152 in human plasma using solidâ€phase extraction. Biomedical Chromatography, 2013, 27, 102-110.	0.8	3
40	Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 363-369.	1.1	3
41	Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatographyâ€“Mass Spectrometric Method. Molecules, 2020, 25, 2209.	1.7	3
42	Pharmacokinetic/Pharmacodynamic Modeling To Predict the Antiplatelet Effect of the Ticagrelor-Loaded Self-Microemulsifying Drug Delivery System in Rats. Molecular Pharmaceutics, 2020, 17, 1079-1089.	2.3	3
43	A Highly Sensitive Liquid Chromatographyâ€“Electrospray Ionizationâ€“Time of Flight/Mass Spectrometric Assay for the Quantitation of 4-Beta-Hydroxycholesterol and Its Application toin vivoCytochrome P450 3a Induction by AGM-130. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 1675-1680.	0.5	2
44	Rapid and simultaneous quantification of a mixture of biopharmaceuticals by a liquid chromatography/quadrupole timeâ€ofâ€flight mass spectrometric method in rat plasma following cassetteâ€dosing. Rapid Communications in Mass Spectrometry, 2018, 32, 889-896.	0.7	2
45	Quantification and Metabolite Identification of Sulfasalazine in Mouse Brain and Plasma Using Quadrupole-Time-of-Flight Mass Spectrometry. Molecules, 2021, 26, 1179.	1.7	2
46	Validation and application of a liquid chromatographyâ€“tandem mass spectrometric method for the determination of G-856 (Cur-61414) in human plasma using semi-automated solid phase extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 887-888, 85-92.	1.2	1
47	Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0834 and its metabolite in human plasma using semi-automated 96-well protein precipitation. Biomedical Chromatography, 2012, 26, 1444-1451.	0.8	1
48	Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method. Applied Sciences (Switzerland), 2021, 11, 9437.	1.3	1
49	Quantitative Analysis of Daporinad (FK866) and Its In Vitro and In Vivo Metabolite Identification Using Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Molecules, 2022, 27, 2011.	1.7	1
50	Fast and Simple Qualitative/Semiâ€Quantitative Analysis of Monoclonal Antibody Mixtures Using Liquid Chromatographyâ€“Electrospray Triple Timeâ€ofâ€Flight Mass Spectrometry. Bulletin of the Korean Chemical Society, 2018, 39, 1380-1384.	1.0	0
51	Study of Ultraâ€Sensitive AMS Method to Identify Drugâ€“Drug Interactions between Ciprofloxacin and Microdose ¹⁴Câ€Caffeine. Bulletin of the Korean Chemical Society, 2018, 39, 773-777.	1.0	0
52	Qualification and application of liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of carisbamate in rat plasma and prediction of its human pharmacokinetics using physiologically based pharmacokinetic modeling. Translational and Clinical Pharmacology, 2020, 28, 147.	0.3	0